Macciò A, Lai P, Santona M C, Pagliara L, Melis G B, Mantovani G
Department of Medical Oncology, University of Cagliari, Italy.
Gynecol Oncol. 1998 Jun;69(3):248-52. doi: 10.1006/gyno.1998.4974.
The serum levels of interleukin-(IL-)1 alpha, IL-1 beta, IL-2, IL-6, TNF alpha, and sIL-2R and the proliferative response of peripheral blood mononuclear cells (PBMC) to phytohemagglutinin (PHA), anti-CD3 monoclonal antibody (mAb), recombinant IL-2 (rIL-2), and the combination of PHA or anti-CD3 mAb with rIL-2 were studied and correlated with serum levels of C-reactive protein (CRP) in women with advanced epithelial ovarian cancer. The expression of CD25 and CD122 subunities of membrane-bound IL-2R on PHA- or anti-CD3 mAb-stimulated PBMC was also studied. In comparisons with the controls, PBMC response to PHA, anti-CD3 mAb, and rIL-2 was significantly lower in the cancer patients. The addition of exogenous rIL-2 to the PBMC cultures increased response in both controls and patients but did not modify the significance of the differences. After stimulation with PHA or anti-CD3 mAb, the percentage of PBMC CD25+ or CD122+ was significantly lower in patients. The serum levels of IL-1 alpha, IL-1 beta, IL-6, TNF alpha, sIL-2R, and CRP were significantly increased in patients compared to the controls. Instead, no differences were observed for serum levels of IL-2. A strong association was found between high serum levels of the above-mentioned cytokines, sIL-2R, and CRP. The results of our study on advanced stage (IIIb-IV) ovarian cancer patients are consistent with the previously reported hypothesis that high IL-6 and/or CRP serum levels may represent an important and independent prognostic factor of the likely outcome in cancer patients.
研究了晚期上皮性卵巢癌女性患者血清白细胞介素 -（IL -）1α、IL - 1β、IL - 2、IL - 6、肿瘤坏死因子α（TNFα）、可溶性白细胞介素 - 2受体（sIL - 2R）水平，以及外周血单个核细胞（PBMC）对植物血凝素（PHA）、抗CD3单克隆抗体（mAb）、重组白细胞介素 - 2（rIL - 2）的增殖反应，以及PHA或抗CD3 mAb与rIL - 2联合使用时的反应，并将这些反应与C反应蛋白（CRP）的血清水平进行关联分析。还研究了PHA或抗CD3 mAb刺激的PBMC上膜结合型白细胞介素 - 2受体（IL - 2R）的CD25和CD122亚基的表达。与对照组相比，癌症患者的PBMC对PHA、抗CD3 mAb和rIL - 2的反应明显较低。在PBMC培养物中添加外源性rIL - 2可增加对照组和患者的反应，但并未改变差异的显著性。经PHA或抗CD3 mAb刺激后，患者PBMC中CD25 +或CD122 +的百分比明显较低。与对照组相比，患者血清中IL - 1α、IL - 1β、IL - 6、TNFα、sIL - 2R和CRP水平显著升高。相反，未观察到IL - 2血清水平的差异。发现上述细胞因子、sIL - 2R和CRP的高血清水平之间存在强关联。我们对晚期（IIIb - IV期）卵巢癌患者的研究结果与先前报道的假设一致，即高IL - 6和/或CRP血清水平可能是癌症患者可能预后的重要独立预后因素。
